Immunisation through vaccines is a key strategic commitment to preventing infections in the face of the health challenge posed by antimicrobial resistance (AMR), that is, the ability of certain microorganisms to survive medications designed to eliminate them. This is one of the conclusions from the event held this Friday in Madrid, organised by  under the theme “Biotechnology for a safer future”, in which HIPRA’s Chief Corporate Affairs & Sustainability Officer, Carlota Gómez, participated.

In this context, the One Health approach carries particular weight, as it recognises the interconnectedness of human, animal, and environmental health, and shapes HIPRA’s innovation policy. In fact, “thanks to the synergies created between our human and animal divisions, HIPRA is uniquely positioned to understand and prevent zoonotic diseases, reducing the use of antibiotics and thus contributing to the fight against antimicrobial resistance,” Gómez stated.

“For HIPRA, One Health represents the way our purpose is defined: we work in animal health and human health, with a strong commitment to prevention and to solutions that connect both worlds, with sustainability as a cross-cutting pillar,” she added.

In the same context, Gómez recalled that HIPRA has over 50 years of experience working on 300 pathogens and developing innovative vaccines for animal health, and that, following the pandemic, it has also been working in human health for the past five years. “This integrated vision is essential to addressing potential health crises, and at this point, the biotechnology industry has an opportunity to drive innovative solutions that strengthen surveillance, prevention, and response capacity,” HIPRA’s executive concluded at the Madrid event.